Clinical Evaluation of Oral Rinse for Xerostomia

NCT ID: NCT04289051

Last Updated: 2022-02-24

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

39 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-19

Study Completion Date

2021-02-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Xerostomia causes a difficulty in eating, have irritated oral tissues, and a poor quality of life. The new oral rinse was designed to reduce the symptoms and improve the patient's quality of life. The objectives of the clinical study is to evaluate the effectiveness of the oral rinse comparing to the placebo product and the control product in the market.

This is a randomized double-blind placebo controlled crossover study with 39 patients receiving treatment. Patients will be randomly allocated to three treatment groups. Patients will use the assigned oral rinse four times a day for two weeks. Dry mouth symptoms and other endpoints will be assessed subjectively and objectively at baseline and Day 14. Patients will be assigned to another treatment after one week wash-out period.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Xerostomia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HYDRAL Oral Rinse

Subjects use the oral rinse four times daily adding to a regular oral hygiene routine with a fluoride toothpaste and a soft tooth brush.

Group Type EXPERIMENTAL

HYDRAL Oral Rinse

Intervention Type DEVICE

Application 4 times a day for two weeks

BIOTENE® Oral Rinse

Intervention Type DEVICE

Application 4 times a day for two weeks

Placebo Oral Rinse

Intervention Type DEVICE

Application 4 times a day for two weeks

BIOTENE® Oral Rinse

Subjects use the oral rinse four times daily adding to a regular oral hygiene routine with a fluoride toothpaste and a soft tooth brush.

Group Type ACTIVE_COMPARATOR

HYDRAL Oral Rinse

Intervention Type DEVICE

Application 4 times a day for two weeks

BIOTENE® Oral Rinse

Intervention Type DEVICE

Application 4 times a day for two weeks

Placebo Oral Rinse

Intervention Type DEVICE

Application 4 times a day for two weeks

Placebo Oral Rinse

Subjects use the oral rinse four times daily adding to a regular oral hygiene routine with a fluoride toothpaste and a soft tooth brush.

Group Type PLACEBO_COMPARATOR

HYDRAL Oral Rinse

Intervention Type DEVICE

Application 4 times a day for two weeks

BIOTENE® Oral Rinse

Intervention Type DEVICE

Application 4 times a day for two weeks

Placebo Oral Rinse

Intervention Type DEVICE

Application 4 times a day for two weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HYDRAL Oral Rinse

Application 4 times a day for two weeks

Intervention Type DEVICE

BIOTENE® Oral Rinse

Application 4 times a day for two weeks

Intervention Type DEVICE

Placebo Oral Rinse

Application 4 times a day for two weeks

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Must have read, understood and signed an informed consent prior to being entered into the study.
2. Must be 18 to 80 years of age, male or female.
3. Have at least 20 natural or restored teeth.
4. Have an unstimulated salivary flow rate \<0.20 ml/minute which represents a significant reduction of normal salivary function
5. Must have subjective xerostomia symptom: minimum level of 4 on a 10 centimeters Visual Analog Scale (VAS) \[How would you score dryness of your mouth?\]
6. Agree not to have a dental prophylaxis or any other elective, non-emergency dental procedures (other than those provided during the study) any time during the study.
7. Agree to abstain from the use of any products for xerostomia other than those provided in the study.
8. Agree to comply with the conditions and schedule of the study.

Exclusion Criteria

1. Physical limitations or restrictions that might preclude normal tooth brushing.
2. Evidence of gross oral pathology, including widespread caries or chronic neglect, extensive restoration, pre-existing gross plaque or soft or hard tissue tumor of the oral cavity.
3. Presence of severe gingivitis with 30 or more sites showing bleeding on probing.
4. Evidence of major oral hard or soft tissue lesions or trauma at the baseline visit as determined by the Investigator/Examiner.
5. Chronic disease with concomitant oral manifestations other than xerostomia
6. Conditions requiring antibiotic treatment prior to dental prophylaxis and invasive procedures, such as heart murmur, history of rheumatic fever, valvular disease or certain prosthetic implants.
7. History of hepatic or renal disease, uncontrolled diabetes, or other serious conditions or transmittable diseases.
8. Subjects who are currently undergoing, or require, extensive dental work, orthodontic treatment or periodontal surgery or orthodontic treatment in the preceding 3 months
9. Currently using bleaching trays
10. History of radiotherapy, head and neck cancer or Sjogren's syndrome.
11. History of significant adverse effects following use of oral hygiene products such as toothpastes and mouthrinses.
12. Subjects who are nursing, pregnant or plan to become pregnant for the duration of the study.
13. Currently breast feeding
14. Eating disorders
15. Recent history of substance abuse
16. Participation in other clinical studies within 14 days of screening
17. Smoking \>10 cigarettes/day
18. Chewing tobacco
19. Daily use of symptom alleviating products against xerostomia within 7 days of screening.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sunstar Americas

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University at Buffalo, The Center for Dental Studies

Buffalo, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CLP-2020-02-01-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Clinical Study New Gel for Xerostomia
NCT04184908 UNKNOWN PHASE1
Hyaluronic Acid in the Treatment of Hyposalivation
NCT07309588 ENROLLING_BY_INVITATION PHASE1/PHASE2